Characteristics of the infused 19-28z–transduced T cells
| Test . | CLL-1 . | CLL-2 . | CLL-3 . | CLL-4 . | CLL-5 . | CLL-6 . | CLL-7 . | CLL-8 . | ALL-1 . | ALL-2 . |
|---|---|---|---|---|---|---|---|---|---|---|
| CD3+ T cells, % | ||||||||||
| Apheresis product | 5.4 | 45 | 7.2 | 5.1 | 15.9 | 6.2 | 25 | 22.5 | 45 | 67 |
| EOP cells | 98 | 100 | 100 | 99 | 98 | 99 | 85 | 100 | 99 | 100 |
| Tumor cells, % | ||||||||||
| Apheresis product | 94 | 4 | 90 | 94 | 50 | 94 | 28 | 69 | 3.1 | 0 |
| EOP cells | 0.1 | 0 | 0 | 0 | 1 | 0 | 1.2 | 0 | 0 | 0.2 |
| CD3+/19-28z CAR+, % | 23 | 31 | 53 | 70 | 32 | 39 | 25 | 39.3 | 8.6 | 4 |
| Cytotoxicity (25:1) | ||||||||||
| Auto-B tumor cells | 58.8 | ND | 52.3 | 48.7 | 33.7 | 59.5 | 35.7 | 28.3 | ND | ND |
| Raji tumor cells | 51.1 | 47.1 | 52.3 | 46.5 | 43.3 | 73.8 | 72.9 | 24.8 | 29.2 | 8.6 |
| Fold expansion after transduction (days in culture) | 53 (17) | 184 (19) | 23.6 (18) | 112 (15) | 191 (18) | 51 (15) | 62.4 (15) | 385 (16) | 49.4 (d11) | 88.5 (d11) |
| Total 1928z+/CD3+ cells infused | 2.5 × 109 | 1.2 × 109 | 1.1 × 109 | 3.2 × 109 | 4 × 108 | 4 × 108 | 7.6 × 108 | 1.4 × 109 | 1.8 × 108 | NA |
| Total CD3+ cells infused | 11.1 × 109 | 3.7 × 109 | 2.1 × 109 | 4.6 × 109 | 1.2 × 109 | 1.0 × 109 | 3.0 × 109 | 3.5 × 109 | 2.1 × 109 | NA |
| Test . | CLL-1 . | CLL-2 . | CLL-3 . | CLL-4 . | CLL-5 . | CLL-6 . | CLL-7 . | CLL-8 . | ALL-1 . | ALL-2 . |
|---|---|---|---|---|---|---|---|---|---|---|
| CD3+ T cells, % | ||||||||||
| Apheresis product | 5.4 | 45 | 7.2 | 5.1 | 15.9 | 6.2 | 25 | 22.5 | 45 | 67 |
| EOP cells | 98 | 100 | 100 | 99 | 98 | 99 | 85 | 100 | 99 | 100 |
| Tumor cells, % | ||||||||||
| Apheresis product | 94 | 4 | 90 | 94 | 50 | 94 | 28 | 69 | 3.1 | 0 |
| EOP cells | 0.1 | 0 | 0 | 0 | 1 | 0 | 1.2 | 0 | 0 | 0.2 |
| CD3+/19-28z CAR+, % | 23 | 31 | 53 | 70 | 32 | 39 | 25 | 39.3 | 8.6 | 4 |
| Cytotoxicity (25:1) | ||||||||||
| Auto-B tumor cells | 58.8 | ND | 52.3 | 48.7 | 33.7 | 59.5 | 35.7 | 28.3 | ND | ND |
| Raji tumor cells | 51.1 | 47.1 | 52.3 | 46.5 | 43.3 | 73.8 | 72.9 | 24.8 | 29.2 | 8.6 |
| Fold expansion after transduction (days in culture) | 53 (17) | 184 (19) | 23.6 (18) | 112 (15) | 191 (18) | 51 (15) | 62.4 (15) | 385 (16) | 49.4 (d11) | 88.5 (d11) |
| Total 1928z+/CD3+ cells infused | 2.5 × 109 | 1.2 × 109 | 1.1 × 109 | 3.2 × 109 | 4 × 108 | 4 × 108 | 7.6 × 108 | 1.4 × 109 | 1.8 × 108 | NA |
| Total CD3+ cells infused | 11.1 × 109 | 3.7 × 109 | 2.1 × 109 | 4.6 × 109 | 1.2 × 109 | 1.0 × 109 | 3.0 × 109 | 3.5 × 109 | 2.1 × 109 | NA |
The average 19-28z vector copy number per cell from CLL-1 to ALL-2 patients was 0.34, 0.54, 0.66, 1.15, 0.81, 1.5, 0.86, 0.62, 0.14, and 0.06, respectively.